Sponsored by Agios Pharmaceuticals, Inc.
For US audiences only
Prescribing Information
Medication Guide
Sponsored by Agios Pharmaceuticals, Inc.
For US
audiences only
LEVEL UP with AQVESME
AQVESME increased hemoglobin by ≥1 g/dL in 42.3% of people vs placebo (1.6%)
In adults
AQVESME is the ONLY treatment for anemia in BOTH non-transfusion-dependent (NTD) and transfusion-dependent (TD), alpha- or beta-thalassemia
AQVESME significantly increases hemoglobin (Hb) in non–transfusion-dependent thalassemia
AQVESME significantly reduces fatigue in non–transfusion-dependent thalassemia
AQVESME significantly reduces transfusion burden in transfusion-dependent thalassemia
Talk to your doctor about AQVESME and whether it may be right for you.
Learn more about AQVESME
Sign up to receive helpful information and resources about AQVESME, including a free patient brochure.